These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21188449)

  • 1. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.
    Akashi N; Matsumoto I; Tanaka Y; Inoue A; Yamamoto K; Umeda N; Tanaka Y; Hayashi T; Goto D; Ito S; Sekiguchi K; Sumida T
    Mod Rheumatol; 2011 Jun; 21(3):267-75. PubMed ID: 21188449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.
    Rhee CK; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim YK; Kim KH; Kim TJ; Kim JW
    Respiration; 2011; 82(3):273-87. PubMed ID: 21659722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.
    Paniagua RT; Chang A; Mariano MM; Stein EA; Wang Q; Lindstrom TM; Sharpe O; Roscow C; Ho PP; Lee DM; Robinson WH
    Arthritis Res Ther; 2010; 12(1):R32. PubMed ID: 20181277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.
    Paniagua RT; Sharpe O; Ho PP; Chan SM; Chang A; Higgins JP; Tomooka BH; Thomas FM; Song JJ; Goodman SB; Lee DM; Genovese MC; Utz PJ; Steinman L; Robinson WH
    J Clin Invest; 2006 Oct; 116(10):2633-42. PubMed ID: 16981009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
    Day E; Waters B; Spiegel K; Alnadaf T; Manley PW; Buchdunger E; Walker C; Jarai G
    Eur J Pharmacol; 2008 Dec; 599(1-3):44-53. PubMed ID: 18938156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells.
    Belle L; Bruck F; Foguenne J; Gothot A; Beguin Y; Baron F; Briquet A
    PLoS One; 2012; 7(12):e52564. PubMed ID: 23285088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery.
    Kim IK; Rhee CK; Yeo CD; Kang HH; Lee DG; Lee SH; Kim JW
    Crit Care; 2013 Jun; 17(3):R114. PubMed ID: 23787115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis.
    Matsumoto I; Zhang H; Yasukochi T; Iwanami K; Tanaka Y; Inoue A; Goto D; Ito S; Tsutsumi A; Sumida T
    Arthritis Res Ther; 2008; 10(3):R66. PubMed ID: 18534002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cells play a crucial role as antigen-presenting cells and collaborate with inflammatory cytokines in glucose-6-phosphate isomerase-induced arthritis.
    Tanaka-Watanabe Y; Matsumoto I; Iwanami K; Inoue A; Goto D; Ito S; Tsutsumi A; Sumida T
    Clin Exp Immunol; 2009 Feb; 155(2):285-94. PubMed ID: 19032549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
    Dewar AL; Cambareri AC; Zannettino AC; Miller BL; Doherty KV; Hughes TP; Lyons AB
    Blood; 2005 Apr; 105(8):3127-32. PubMed ID: 15637141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
    Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD
    Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nilotinib protects the murine liver from ischemia/reperfusion injury.
    Ocuin LM; Zeng S; Cavnar MJ; Sorenson EC; Bamboat ZM; Greer JB; Kim TS; Popow R; DeMatteo RP
    J Hepatol; 2012 Oct; 57(4):766-73. PubMed ID: 22641092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.
    Konig H; Holtz M; Modi H; Manley P; Holyoake TL; Forman SJ; Bhatia R
    Leukemia; 2008 Apr; 22(4):748-55. PubMed ID: 18273048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate: an innovation in treatment of autoimmune diseases.
    Azizi G; Mirshafiey A
    Recent Pat Inflamm Allergy Drug Discov; 2013 Sep; 7(3):259-67. PubMed ID: 23947692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
    Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.
    Chu S; Alexiadis M; Fuller PJ
    Gynecol Oncol; 2008 Jan; 108(1):182-90. PubMed ID: 18028988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase.
    Iwanami K; Matsumoto I; Tanaka-Watanabe Y; Inoue A; Mihara M; Ohsugi Y; Mamura M; Goto D; Ito S; Tsutsumi A; Kishimoto T; Sumida T
    Arthritis Rheum; 2008 Mar; 58(3):754-63. PubMed ID: 18311788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice.
    Koyama K; Hatsushika K; Ando T; Sakuma M; Wako M; Kato R; Haro H; Sugiyama H; Hamada Y; Ogawa H; Nakao A
    Mod Rheumatol; 2007; 17(4):306-10. PubMed ID: 17694264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells.
    Belloc F; Airiau K; Jeanneteau M; Garcia M; Guérin E; Lippert E; Moreau-Gaudry F; Mahon FX
    Leukemia; 2009 Apr; 23(4):679-85. PubMed ID: 19158834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
    Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M
    Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.